 11. Male subjects and their female partner who are of child-bearing potential as defined in Inclusion 10, and are not practicing total abstinence, must agree to use two forms of highly effective contraception from the last menstrual period of their female partner prior to randomization or use a double barrier method as described above until they are on two forms of highly effective contraception for at least one menstrual cycle, during study treatment, and for 3 months or 6 months if they received dacarbazine after the final dose of study treatment. If currently abstinent, must agree to use a double barrier method of contraception if they become sexually active, or until they are on two forms of highly effective contraception as described above. 